

SEQUENCE LISTING

```
<110> Schenk, Dale B.
      Elan Pharmaceuticals
<120> Prevention and Treatment of Amyloidogenic Diseases
<130> 015270-005913US
<140> US 09/724,953
<141> 2000-11-28
<150> US 09/585,817
<151> 2000-06-01
<150> US 60/137,010
<151> 1999-06-01
<160> 34
<170> PatentIn Ver. 2.1
<210> 1
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:influenza
      hemagglutinin HA 307-319 universal T-cell epitope
<400> 1
Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr
                                                               RECEIVED
 1
                  5
                                                                MAY 2 9 2003
<210> 2
<211> 13
                                                            TECH CENTER 1600/2900
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: PADRE universal
      T-cell epitope
<220>
<221> MOD RES
<222> (3)
<223> Xaa = any amino acid
<400> 2
Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala
                  5
                                     10
<210> 3
<211> 16
<212> PRT
<213> Artificial Sequence
```

```
<220>
<223> Description of Artificial Sequence:malaria CS T3
      epitope universal T-cell epitope
<400> 3
Glu Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser Val Phe Asn Val
                                     10
<210> 4
<211> 10
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Hepatitis B
      surface antigen HBsAg 19-28 universal T-cell
      epitope
Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile
                  5
<210> 5
<211> 19
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence:heat shock
      protein 65 hsp65 153-171 universal T-cell epitope
<400> 5
Asp Gln Ser Ile Gly Asp Leu Ile Ala Glu Ala Met Asp Lys Val Gly
 1
                  5
Asn Glu Gly
<210> 6
<211> 14
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence:bacillus
      Calmette-Guerin universal T-cell epitope
Gln Val His Phe Gln Pro Leu Pro Pro Ala Val Lys Leu
                  5
<210> 7
<211> 15
<212> PRT
<213> Artificial Sequence
```

<220>

```
<223> Description of Artificial Sequence:tetanus toxoid
      TT 830-844 universal T-cell epitope
<400> 7
Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu
                  5
<210> 8
<211> 21
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence:tetanus toxoid
      TT 947-967 universal T-cell epitope
Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser
                                      10
Ala Ser His Leu Glu
             20
<210> 9
<211> 16
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: HIV gp120 T1
      universal T-cell epitope
Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala
                  5
                                      10
<210> 10
<211> 22
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: AN90549 (Abeta
      1-7/tetanus toxoid 830-844 in a MAP4
      configuration)
<400> 10
Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe
Ile Gly Ile Thr Glu Leu
             20
<210> 11
<211> 28
<212> PRT
```

<213> Artificial Sequence

```
<220>
<223> Description of Artificial Sequence: AN90550 (Abeta
      1-7/tetanus toxoid 947-967 in a MAP4
      configuration)
<400> 11
Asp Ala Glu Phe Arg His Asp Phe Asn Asn Phe Thr Val Ser Phe Trp
Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu
             20
<210> 12
<211> 43
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: AN 90542 (Abeta
      1-7/tetanus toxoid 830-844 + 947-967 in a linear
      configuration)
<400> 12
Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe
Ile Gly Ile Thr Glu Leu Phe Asn Asn Phe Thr Val Ser Phe Trp Leu
                                  25
Arg Val Pro Lys Val Ser Ala Ser His Leu Glu
                              40
<210> 13
<211> 22
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: AN 90576 (Abeta
      3-9/tetanus toxoid 830-844 in a MAP4
      configuration)
<400> 13
Glu Phe Arg His Asp Ser Gly Gln Tyr Ile Lys Ala Asn Ser Lys Phe
                  5
Ile Gly Ile Thr Glu Leu
             20
<210> 14
<211> 20
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: AN90562 (Abeta
```

1-7/peptide on linear confornmation)

```
<220>
 <221> MOD RES
 <222> (3)
 <223> Xaa = any amino acid
 <400> 14
 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Asp Ala Glu
                                       10
 Phe Arg His Asp
               20
 <210> 15
 <211> 34
 <212> PRT
 <213> Artificial Sequence
<220>
 <223> Description of Artificial Sequence: AN90543 (Abeta
       1-7 X 3/peptide in linear conformation)
 <220>
 <221> MOD RES
 <222> (24)
 <223> Xaa = any amino acid
 <400> 15
 Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala
 Glu Phe Arg His Asp Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala
                                   25
 Ala Ala
 <210> 16
 <211> 34
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: fusion protein
       with Abeta immunogenic epitope
 <220>
 <221> MOD_RES
 <222> (3)
 <223> Xaa = any amino acid
 <400> 16
 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Asp Ala Glu
 Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg
```

His Asp

```
<210> 17
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: fusion protein
      with Abeta immunogenic epitope
<220>
<221> MOD_RES
<222> (10)
<223> Xaa = any amino acid
<400> 17
Asp Ala Glu Phe Arg His Asp Ala Lys Xaa Val Ala Ala Trp Thr Leu
                                      10
Lys Ala Ala Ala
             20
<210> 18
<211> 24
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: fusion protein
      with Abeta immunogenic epitope
<400> 18
Asp Ala Glu Phe Arg His Asp Ile Ser Gln Ala Val His Ala Ala His
 1
                  5
Ala Glu Ile Asn Glu Ala Gly Arg
             20
<210> 19
<211> 24
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: fusion protein
      with Abeta immunogenic epitope
<400> 19
Phe Arg His Asp Ser Gly Tyr Ile Ser Gln Ala Val His Ala Ala His
                                      10
Ala Glu Ile Asn Glu Ala Gly Arg
```

<210> 20

20

```
<211> 24
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: fusion protein
      with Abeta immunogenic epitope
<400> 20
Glu Phe Arg His Asp Ser Gly Ile Ser Gln Ala Val His Ala Ala His
                                      10
Ala Glu Ile Asn Glu Ala Gly Arg
             20
<210> 21
<211> 34
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: fusion protein
      with Abeta immunogenic epitope
<400> 21
Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr Asp Ala Glu
                  5
                                      10
Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg
                                  25
His Asp
<210> 22
<211> 27
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: fusion protein
      with Abeta immunogenic epitope
<400> 22
Asp Ala Glu Phe Arg His Asp Pro Lys Tyr Val Lys Gln Asn Thr Leu
                                      10
Lys Leu Ala Thr Asp Ala Glu Phe Arg His Asp
             20
<210> 23
<211> 34
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: fusion protein
```

with Abeta immunogenic epitope

```
<400> 23
Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala
Glu Phe Arg His Asp Pro Lys Tyr Val Lys Gln Asn Thr Leu Lys Leu
                                 25
Ala Thr
<210> 24
<211> 27
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: fusion protein
      with Abeta immunogenic epitope
<400> 24
Asp Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Pro Lys
Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr
             20
<210> 25
<211> 136
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: fusion protein
      with Abeta immunogenic epitope
<400> 25
Asp Ala Glu Phe Arg His Asp Pro Lys Tyr Val Lys Gln Asn Thr Leu
                  5
Lys Leu Ala Thr Glu Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser
Val Phe Asn Val Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile
Thr Glu Leu Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro
Lys Val Ser Ala Ser His Leu Glu Asp Ala Glu Phe Arg His Asp Asp
Ala Glu Phe Arg His Asp Asp Ala Glu Phe Arg His Asp Asp Ala Glu
Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile
```

105

```
Thr Glu Leu Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro
                            120
Lys Val Ser Ala Ser His Leu Glu
                        135
    130
<210> 26
<211> 44
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: fusion protein
      with Abeta immunogenic epitope
Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe
                                      10
Ile Gly Ile Thr Glu Leu Cys Phe Asn Asn Phe Thr Val Ser Phe Trp
             20
Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu
                             40
<210> 27
<211> 51
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: fusion protein
      with Abeta immunogenic epitope
<400> 27
Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe
Ile Gly Ile Thr Glu Leu Cys Phe Asn Asn Phe Thr Val Ser Phe Trp
             20
Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu Asp Ala Glu Phe
Arg His Asp
     50
<210> 28
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: fusion protein
```

<400> 28

resin of Lys-Gly-Cys

with Abeta immunogenic epitope on a 2 branched

```
Asp Ala Glu Phe Arg His Asp Gln Tyr Ile Lys Ala Asn Ser Lys Phe
Ile Gly Ile Thr Glu Leu
             20
<210> 29
<211> 26
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence:synuclein
      fusion protein in MAP-4 configuration
<400> 29
Glu Gln Val Thr Asn Val Gly Gly Ala Ile Ser Gln Ala Val His Ala
Ala His Ala Glu Ile Asn Glu Ala Gly Arg
             20
<210> 30
<211> 13
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Abeta 1-12
      peptide with Cys added
<400> 30
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val Cys
                  5
<210> 31
<211> 6
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Abeta 1-5
      peptide with Cys added
<400> 31
Asp Ala Glu Phe Arg Cys
<210> 32
<211> 12
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Abeta 33-42
      peptide with Cys added
```

```
<220>
<221> MOD_RES
<222> (2)
<223> Xaa = amino-heptanoic acid
<400> 32
Cys Xaa Gly Leu Met Val Gly Gly Val Val Ile Ala
                  5
<210> 33
<211> 20
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Abeta 13-28
      peptide with Cys added
<220>
<221> MOD RES
<222> (1)
<223> Xaa = acetyl-asparagine
<400> 33
Xaa His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser
                                      10
Asn Lys Gly Gly Cys
                 20
<210> 34
<211> 42
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Abeta 42
<400> 34
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
Gly Leu Met Val Gly Gly Val Val Ile Ala
```

35